A Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 (Filibuvir) Following Single Oral Administrations Of PF-00868554 (Filibuvir) Under Fasting Conditions In Japanese Healthy Adult Volunteers.
Latest Information Update: 28 Apr 2010
At a glance
- Drugs Filibuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Pfizer
- 27 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Mar 2010 New trial record